40+ Presentations from Top Biopharma at PEGS Europe

The CD25 Antibody RG6292 Selectively Depletes Tregs while Preserving IL-2 Signaling and CTL Activity for Tumor Control
Maria Amann, Senior Scientist, Drug Development, Roche Innovation Center Zurich

Combining Random Mutagenesis, Structure-Guided Design, Next-Generation Sequencing and in silico Prediction to Optimize Polyreactivity and Other Biophysical Properties in Therapeutic Antibodies
James R. Apgar, PhD, Associate Research Fellow, Global Biotherapeutics Technologies, Pfizer Inc.

Predicting Antibody Developability through Experimental and in silico Approaches
Marc Bailly, PhD, Principal Scientist, Merck Research Labs

PD-1 Antibodies as Precision Medicine Informed Mono- and Combination Therapies Are Transforming Cancer Care
Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development; CMO, Merck, Sharp and Dohme

LC-MS Characterization of Viral Vector-Based Gene Therapy Products
Jill Bradley-Graham, PhD, Scientist, BioAnalytics Characterization, Sanofi Genzyme

DuoHexaBody-CD37
Esther C.W. Breij, PhD, Senior Director, Translational Research, Translational Research, Genmab BV

Accelerated Predictive Stability for Biologicals and Vaccines
Didier Clenet, Senior Scientist, Formulation & Stability & Bioprocess R&D, Sanofi Pasteur

Characterization of Half Antibodies and LC Swab Variants of a Bispecific Antibody during Clone Selection
Manuel Diez, PhD, Functional Lead, Characterization, Novartis

Is NMR Spectroscopy the Right Tool to Monitor the HOS of Biologics?
Camille Doyen, PhD, Scientist, Biophysics, Sanofi

Antibody CDR Design Using High-Capacity Machine Learning
Stefan Ewert, PhD, Senior Investigator, Biologics Center, Novartis Institutes for Biomedical Research

Rational Selection of Building Blocks for the Assembly of Bispecific Antibodies
Danyang Gong, PhD, Scientist, Amgen Inc.

How Analytical and Biological Characterization Translates into a Comprehensive and Smart Control Strategy for Commercial Manufacturing
Dirk Haubert, PhD, Analytical Project Lead, Biologics, Novartis Pharma AG

A Novel Tumor Selective Anti-CD137 Agonist Antibody Activated by Elevated Extracellular ATP in Tumor Microenvironment
Yuji Hori, PhD, Research Scientist, Discovery Biological, Chugai Pharmaceutical Co. Ltd.

Analytical Control Strategy for Antisense Oligonucleotide
Hong Jiang, Senior Scientist, Analytical Development, Biogen

Design and Validation of a Novel Engineered, FcγRIIb-Selective Fc Platform for Therapeutic Antibody Development
Gavin C. Jones, PhD, Investigator, GlaxoSmithKline

Development of a High-Throughput cIEF Method for Quantification of Full and Empty Viral Particles for Cell and Gene Therapies
Jenifer Kaplan, PhD, Principal Scientist I, Novartis Institutes for Biomedical Research

Engineering Antibodies for Next-Generation Cancer Immunotherapy
Christian Klein, PhD, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED

Intrinsic Physiochemical Profile of Biological Medicines
Sandeep Kumar, PhD, Senior Research Fellow, Computational Biochemistry and Bioinformatics, Boehringer Ingelheim Pharmaceuticals

Characterization and Mitigation of Pre-Existing Immuno-Reactivity Directed to a Motif in the Fc Region of an IgG4 Monoclonal Antibody Therapeutic
Ching-Ha (Vicky) Lai, PhD, Senior Staff Scientist, Bioanalytical Sciences, Regeneron Pharmaceuticals, Inc.

Development of an Anion Exchange Chromatography Assay for Determining Empty and Full AAV Capsid Content in AAV6.2
Thomas Linke, Senior Scientist, Process Development, AstraZeneca

A Novel Hydrogen Peroxide Evolved CHO Host Can Improve the Expression of Difficult-to-Express Bispecific Antibodies
Rajesh Mistry, Senior Scientist, BioPharmaceuticals Development R&D, AstraZeneca

To Sub 10 pM Affinity and Beyond! Discovery of a Next-Generation Highly Potent Long-Acting Anti IL-5 Antibody
Martin A. Orecchia, PhD, Team Leader, Antibody Discovery, GlaxoSmithKline

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of RO7297089, a Novel Anti-BCMA/CD16a Bispecific Antibody for the Treatment of Multiple Myeloma
Ayse Meric Ovacik, PhD, Scientist, Developmental Sciences, Genentech, Inc.

Analytical Ultracentrifugation: An Auxiliary Tool for Vector Characterization
Robert Pletzenauer, Head of Process Analytics, Gene Therapy, Process Development, Takeda

Characterization of Adeno-Associated Virus-Based Gene Therapy Products by Mass Spectrometry
Yi Pu, PhD, Scientist II, Analytical Development, Biogen

HCP Analysis by LCMS for Biosimilars
Veronika Reisinger, PhD, Lab Head, Physico Chemical Characterization, Novartis AG

Advancing Mass Spectrometry Technology in cGMP Environments
Da Ren, PhD, Scientific Director, Process Development, Amgen Inc.

Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein through Structure-Guided Design
Timothy Riley, PhD, Scientist, Amgen Inc.

Characterization and Monitoring of Cell Therapy Attributes Using Mass Spectrometry
Richard Rogers, PhD, Principal Scientist, Juno Therapeutics, a Bristol-Myers Squibb Co.

How Target Biology Drives Bispecific Antibody Product Discovery
Janine Schuurman, PhD, Senior Vice President, Antibody Research & Technology, Research & Innovation, Genmab BV

Is There Safe Storage Temperature for Frozen and Freeze-Dried Biologicals?
Evgenyi Y. Shalaev, PhD, Research Investigator, Pharmaceutical Development, AbbVie, Inc.

A Novel Next-Generation T Cell Bispecific Antibody Platform
Feng Shu, PhD, Senior Researcher, Chugai Pharmabody Research Pte Ltd.

Ultra-Dilute Solution Measurements of Antibody Self-Association
Charles G. Starr, PhD, Scientist, Developability & Preformulation Sciences, Sanofi Group

Strategies for Greater Expression and Production
Michaela Strotbek, PhD, Bio Process and Analytical Development, Boehringer Ingelheim Pharma GmbH & Co. KG

NMR Tools for the Assessment of Antibody-Drug Candidates Aggregation State
Pablo Trigo Mourino, PhD, Senior Scientist, Analytical Research & Development, MSD

FAP-CD40, a Novel Tumor-Stroma Targeted CD40 Agonist, Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Anti-Tumor Immunity
Christine Trumpfheller, PhD, Senior Scientist, Roche Innovation Center Zurich

Validation of huFcRn Transgenic Mouse Model to Screen Novel Fc-Engineered Monoclonal and Multi-Specific Antibodies
Delphine Valente, PhD, Head, Pharmacokinetics, Modeling and Simulations, Sanofi

Using Neural Networks to Identify Particles
Bernhard Valldorf, PhD, Principal Scientist & Lab Head, Formulation Development, EMD Serono

Screening for Protein-Protein Interactions with Asymmetrical Flow Field-Flow Fractionation
Per-Olof Wahlund, PhD, Specialist, Biophysics & Injectable Formulation 2, Novo Nordisk AS

Structures of Mouse and Human GITR-GITRL Complexes Reveal Unique TNFSF Interactions
Feng Wang, PhD, Associate Director, Recombinant Proteins, Bristol-Myers Squibb

The Role of Monoclonal Antibody Therapeutics in Tackling Global Health Challenges
Pauline Williams, CBE, MBBCh, FFPM, FMedSci, Senior Vice President and Head of Global Health R&D, GlaxoSmithKline

Native SEC-MS for Characterizing Therapeutic Monoclonal Antibodies: A Glimpse in the Formation Mechanism of Antibody Aggregates
Jing Xu, PhD, Scientist I, Analytical Chemistry, Biogen

Bioanalytical Strategies and Methodologies for Assessing PK and Immunogenicity of Cell/Gene Therapy Products
Tong-Yuan Yang, PhD, Senior Director & Head, PK and Immunogenicity Assay Development, Biologics Development Sciences, Janssen R&D, LLC

Efficient NK Cell Redirection by Targeting NKp30
Stefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Merck KGaA